Kyntra Bio Inc (NASDAQ:KYNB) Given Average Rating of “Moderate Buy” by Analysts

Shares of Kyntra Bio Inc (NASDAQ:KYNB) have earned an average rating of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $37.25.

A number of brokerages have recently weighed in on KYNB. Rodman & Renshaw initiated coverage on Kyntra Bio in a research report on Tuesday, June 9th. They set a “buy” rating and a $30.00 target price on the stock. Weiss Ratings upgraded shares of Kyntra Bio from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, August 14th. Lake Street Capital began coverage on shares of Kyntra Bio in a report on Thursday. They set a “buy” rating and a $41.00 price objective on the stock. Oppenheimer started coverage on shares of Kyntra Bio in a report on Monday, July 6th. They set an “outperform” rating and a $35.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $43.00 price objective on shares of Kyntra Bio in a report on Tuesday, September 1st.

Kyntra Bio Stock Performance

Shares of NASDAQ:KYNB opened at $7.07 on Friday. Kyntra Bio has a 52-week low of $6.32 and a 52-week high of $12.58. The business’s 50 day simple moving average is $7.45 and its two-hundred day simple moving average is $7.18. The firm has a market cap of $28.63 million, a P/E ratio of 0.16 and a beta of 1.06.

Hedge Funds Weigh In On Kyntra Bio

An institutional investor recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC acquired a new position in shares of Kyntra Bio Inc (NASDAQ:KYNB) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned approximately 0.26% of Kyntra Bio as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 72.71% of the company’s stock.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.